09/12/2020 – LEUVEN, BELGIUM
Quirem Medical, a Terumo company, is awarded top 3 innovative medical device in the 2019 Belgian Galenus prize with the innovative Holmium-166 SIRT diagnostic scout dose product QuiremScout™.
The Galenus prize recognizes and rewards outstanding achievements that improve the global human condition through the development of innovative therapies1. It was created in France in 1970 by a pharmacist named Roland Mehl with the aim to advance pharmaceutical research. Recently, the Prix Galien award is also granted to innovative medical devices.2
The role of QuiremScout™ microspheres is to evaluate the expected safety and efficacy of the Selective Internal Radiation Therapy (SIRT). QuiremScout™ microspheres are based on the same Holmium-166 microspheres as the therapeutic treatment (QuiremSpheres™). QuiremScout™ microspheres are intended to evaluate lung-shunt3 and extrahepatic deposition3 as part of the SIRT work-up. Moreover, they are intended for evaluation of the intrahepatic distribution3 during the work-up, which can be used to plan the SIRT treatment.4
Currently, 99mTc-MAA is most often used during the pre-treatment work-up of the SIRT treatment algorithm3.
However, QuiremScout™ has recently proven to be more accurate in terms of intrahepatic targeting5 and lung shunt assessment6 compared to 99mTc-MAA during the work-up. The usage of QuiremScout™ microspheres may allow physicians to improve their SIRT treatment planning.3
Recent clinical results continue to support the validation of QuiremScout™ microspheres in patient selection and planning as part of the Holmium Platform, such as the latest publication in the Lancet Oncology Journal from UMC Utrecht for the non-randomized HEPAR PLuS study7, which included Neuroendocrine tumor (NET) patients with liver metastasis after systemic radiation therapy with 177Lu-Dotatate.
The Holmium platform consists of three integrated products (QuiremScout™, QuiremSpheres™ & Q-suite™), which equips physicians with the necessary tools to optimize SIRT outcomes through more individualized treatment.
“QuiremScout is part of the Holmium platform that enables physicians to perform Selective intra-arterial radiation therapy. This technology uniquely allows a fine patient selection and individualized treatment for better outcomes. At Terumo, we are proud of this important recognition by the community.”, said Laurent Domas, Vice President Global Interventional Oncology & Therapy Development, Terumo Interventional Systems.
Learn more about SIRT, the Holmium Platform and how patients with non-resectable liver disease may benefit from QuiremScout™ microspheres.
Instructions for Use- QuiremScout™ (rev 05)
Chiesa & Maccauro, 2020 EJNMM
Smits et al., 2019 EJNMM
Elschot et al., 2014 EJNMM
Braat et. Al. 2020, Lancet Oncology